EU đặt mua 220.000 liệu trình điều trị COVID-19 của GlaxoSmithKline
Ngày 28/7, Liên minh châu Âu (EU) cho biết đã ký một thỏa thuận với công ty dược phẩm GlaxoSmithKline của Anh về việc cung cấp lên đến 220.000 liệu trình thuốc Sotrovimab điều trị bệnh nhân COVID-19 bằng kháng thể đơn dòng mà hãng này đang phát triển. GlaxoSmithKline cùng ngày cũng đã xác nhận thỏa thuận này.
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
Bình luận
Xin vui lòng gõ tiếng Việt có dấu